EU đặt mua 220.000 liệu trình điều trị COVID-19 của GlaxoSmithKline
Ngày 28/7, Liên minh châu Âu (EU) cho biết đã ký một thỏa thuận với công ty dược phẩm GlaxoSmithKline của Anh về việc cung cấp lên đến 220.000 liệu trình thuốc Sotrovimab điều trị bệnh nhân COVID-19 bằng kháng thể đơn dòng mà hãng này đang phát triển. GlaxoSmithKline cùng ngày cũng đã xác nhận thỏa thuận này.
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
Bình luận
Xin vui lòng gõ tiếng Việt có dấu